Takeaways: Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a rec...
Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways: The acquisition turns Jamieson into Kirin’s North American foundation alongside Blackmores and FANCL, creating a multi‑brand global preventative health portfolio that can leverag...
Takeaways: GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, ha...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
